title: Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database.
authors.affiliation: Amylin Pharmaceuticals, San Diego, California, USA. jennie.best@amylin.com
authors.forename: Jennie H
authors.initials: JH
authors.lastname: Best
authors.forename: Byron J
authors.initials: BJ
authors.lastname: Hoogwerf
authors.forename: William H
authors.initials: WH
authors.lastname: Herman
authors.forename: Elise M
authors.initials: EM
authors.lastname: Pelletier
authors.forename: Daniel B
authors.initials: DB
authors.lastname: Smith
authors.forename: Made
authors.initials: M
authors.lastname: Wenten
authors.forename: Mohamed A
authors.initials: MA
authors.lastname: Hussein